VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
Taking everything into account, VX1 scores 6 out of 10 in our fundamental rating. VX1 was compared to 72 industry peers in the Biotechnology industry. VX1 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VX1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
VX1 had negative earnings in the past year.
VX1 had a negative operating cash flow in the past year.
Of the past 5 years VX1 4 years were profitable.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1's Return On Assets of -4.32% is fine compared to the rest of the industry. VX1 outperforms 65.28% of its industry peers.
VX1 has a Return On Equity of -5.99%. This is in the better half of the industry: VX1 outperforms 69.44% of its industry peers.
The Return On Invested Capital of VX1 (15.51%) is better than 91.67% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.35%. This is above the industry average of 12.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROIC | 15.51% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
1.3 Margins
VX1's Operating Margin of 37.91% is amongst the best of the industry. VX1 outperforms 93.06% of its industry peers.
In the last couple of years the Operating Margin of VX1 has grown nicely.
VX1's Gross Margin of 86.03% is amongst the best of the industry. VX1 outperforms 80.56% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), VX1 is creating some value.
VX1 has less shares outstanding than it did 1 year ago.
The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
VX1 has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 13.35 indicates that VX1 is not in any danger for bankruptcy at the moment.
VX1's Altman-Z score of 13.35 is amongst the best of the industry. VX1 outperforms 91.67% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
VX1 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. VX1 outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.35 |
ROIC/WACC1.58
WACC9.83%
2.3 Liquidity
VX1 has a Current Ratio of 2.65. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio of 2.65. This is in the better half of the industry: VX1 outperforms 61.11% of its industry peers.
A Quick Ratio of 2.29 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Quick ratio of 2.29. This is in the better half of the industry: VX1 outperforms 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
The earnings per share for VX1 have decreased strongly by -102.42% in the last year.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
The Revenue has grown by 8.98% in the past year. This is quite good.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
3.2 Future
VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 152.83% yearly.
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.19% yearly.
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
VX1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 22.20, VX1 is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 83.33% of the companies listed in the same industry.
VX1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 37.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.2 |
4.2 Price Multiples
VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 25.55 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has a very decent profitability rating, which may justify a higher PE ratio.
VX1's earnings are expected to grow with 332.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y753.07%
EPS Next 3Y332.19%
5. Dividend
5.1 Amount
No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (7/28/2025, 7:00:00 PM)
402
+2 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap103.23B
Analysts75
Price Target445.85 (10.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.13%
Min EPS beat(2)-7.2%
Max EPS beat(2)-3.07%
EPS beat(4)1
Avg EPS beat(4)-133.54%
Min EPS beat(4)-527.57%
Max EPS beat(4)3.69%
EPS beat(8)4
Avg EPS beat(8)-65%
EPS beat(12)7
Avg EPS beat(12)-42.16%
EPS beat(16)10
Avg EPS beat(16)-29.51%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)2.68%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.75%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-0.27%
PT rev (3m)-0.38%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-0.84%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.2 | ||
| P/S | 10.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.29 | ||
| P/tB | 8.04 | ||
| EV/EBITDA | 25.55 |
EPS(TTM)-0.35
EYN/A
EPS(NY)18.11
Fwd EY4.5%
FCF(TTM)-4.2
FCFYN/A
OCF(TTM)-3.28
OCFYN/A
SpS37.09
BVpS55.12
TBVpS50.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROCE | 22.04% | ||
| ROIC | 15.51% | ||
| ROICexc | 22.97% | ||
| ROICexgc | 26.06% | ||
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% | ||
| FCFM | N/A |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
ROICexc(3y)45.4%
ROICexc(5y)50.15%
ROICexgc(3y)65.51%
ROICexgc(5y)78.06%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 137.41% | ||
| Cap/Sales | 2.5% | ||
| Interest Coverage | 181.38 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | 13.35 |
F-Score4
WACC9.83%
ROIC/WACC1.58
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%
EBIT growth 1Y-1.84%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year827.23%
EBIT Next 3Y131%
EBIT Next 5Y70.83%
FCF growth 1Y-132.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.06%
OCF growth 3YN/A
OCF growth 5YN/A